Coventry and West London Build a Route Through the Scale-Up Gap

The new Scale-up Pathway linking the West Midlands with WestTech London is a sensible response to a stubborn commercial problem: promising science rarely fails because it lacks a map of available facilities.

It fails when technical progress, manufacturability and real customer demand are discovered in the wrong order.

Convened by the University of Warwick and Imperial College London, the pathway is intended to connect deep-tech companies with research expertise, specialist space, investment, talent, suppliers and production capability across the two regions. It is aimed at businesses moving from research into prototyping, demonstration, small-scale production and industrial manufacture.

For the West Midlands, that is a more useful proposition than another broad innovation-network announcement. The region’s advantage is not simply that it has a manufacturing heritage. It is that a company developing a battery technology, medical device, engineered material or clean-energy system can encounter the practical realities of production earlier: component availability, tolerances, quality systems, service needs and the economics of making more than a handful of units.

The important connection is commercial, not geographic

The pathway describes London and the West Midlands as complementary ecosystems. That is plausible, but complementarity only becomes valuable when it changes the questions a growing company asks.

A research-led venture may begin with evidence that its technology works. Its next decisions are more difficult: who experiences the problem acutely enough to change supplier or behaviour; what must the product prove in a live setting; which features add cost without improving adoption; and whether a potential buyer can introduce it without redesigning their own operation.

Those are market and service-design questions as much as engineering questions. They should shape prototype briefs, pilot partners and manufacturing choices well before a business commits to a larger facility.

Scale-up works best when customer evidence and production evidence arrive together, not as separate handovers.

The West Midlands can contribute unusually well here. Its manufacturing base gives founders access to people who understand the difference between an impressive demonstration and a repeatable product. But that practical capability should be paired with disciplined discovery among users, buyers, installers and service teams. A prototype that performs in a laboratory but creates friction for procurement, maintenance or training has not crossed the commercial gap.

A pathway needs cases, not just connections

The announced offer spans sectors including life sciences, biotech, energy, battery technology, climate technology, security and medtech. That breadth makes sense at the level of infrastructure. It is less useful when developing a route to market.

A medtech company may need evidence from clinicians, patients and overstretched operational teams. A battery business may need confidence from vehicle makers, suppliers and safety specialists. An industrial software firm may need to show that operators can use its product without slowing an already pressured line.

Each needs a different definition of a viable first market. The pathway’s strongest contribution would therefore be to help firms identify these decision-makers early, test the commercial assumptions behind a technical roadmap and find production partners able to challenge it.

This is also where the partnership can avoid confusing access with progress. Introductions to investors, laboratories and factories are valuable, but they are inputs. Progress is a clearer proposition, a credible pilot, a manufacturing plan shaped by demand, and evidence that a customer can adopt the result at scale.

What success should look like in the West Midlands

The initiative arrives as the region places renewed emphasis on industrial growth and on retaining more of the value created by British research. That ambition will be judged less by the number of organisations attached to the pathway than by the businesses that move through it.

For West Midlands firms, the practical opportunity is to treat the link with West London as a route to sharper commercial learning, rather than a prestige association. For the pathway’s organisers, the useful measure will be whether founders reach better-informed go-to-market decisions before expensive production commitments are made.

If that happens, Coventry, Birmingham and the wider region will not merely be places where innovation is made. They will be places where it learns what customers will actually buy, use and keep using.